The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Ibrutinib (Imbruvica) for Mantle Cell Lymphoma
(Final Recommendation Posted as of July 19, 2016)
Cobimetinib (Cotellic) for Metastatic Melanoma
(Notification to Implement issued as of July 18, 2016)
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
(Pending Submission as of June 15, 2016)